Nasdaq:CTMXPublished
CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics
- CytomX to receive $5 million preclinical milestone payment - - The CytomX and Regeneron collaboration began in 2022 and was expanded in June 2026 - EMERYVILLE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc.